The crucial role of cancer stem cells (CSCs) in the pathology of malignant diseases has been extensively studied during the last decade. Nestin, a class VI intermediate filament protein, was originally detected in neural stem cells during development. Its expression has also been reported in different tissues under various pathological conditions. Specifically, nestin has been shown to be expressed in transformed cells of various human malignancies, and a correlation between its expression and the clinical course of some diseases has been proved. Furthermore, the coexpression of nestin with other stem cell markers was described as a CSC phenotype that was subsequently verified using tumorigenicity assays. The primary aim of this review is to summarize the recent findings regarding nestin expression in CSCs, its possible role in CSC phenotypes, particularly with respect to capacity for self-renewal, and its utility as a putative marker of CSCs.

• Klíčová slova
• Cancer stem cells, cytoskeleton, intermediate filaments, nestin, tumor markers,
• MeSH
• lidé MeSH
• nádorové biomarkery metabolismus   MeSH
• nádorové kmenové buňky metabolismus   MeSH
• nádory metabolismus   patologie   MeSH
• nestin metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• nádorové biomarkery MeSH
• NES protein, human MeSH Prohlížeč
• nestin MeSH

CD133 (also known as prominin-1) is a cell surface glycoprotein that is widely used for the identification of stem cells. Furthermore, its glycosylated epitope, AC133, has recently been discussed as a marker of cancer stem cells in various human malignancies. During our recent experiments on rhabdomyosarcomas (RMS), we unexpectedly identified an atypical nuclear localization of CD133 in a relatively stable subset of cells in five RMS cell lines established in our laboratory. To the best of our knowledge, this atypical localization of CD133 has not yet been proven or analyzed in detail in cancer cells. In the present study, we verified the nuclear localization of CD133 in RMS cells using three independent anti-CD133 antibodies, including both rabbit polyclonal and mouse monoclonal antibodies. Indirect immunofluorescence and confocal microscopy followed by software cross-section analysis, transmission electron microscopy and cell fractionation with immunoblotting were also employed, and all the results undeniably confirmed the presence of CD133 in the nuclei of stable minor subpopulations of all five RMS cell lines. The proportion of cells showing an exclusive nuclear localization of CD133 ranged from 3.4 to 7.5%, with only minor differences observed among the individual anti-CD133 antibodies. Although the role of CD133 in the cell nucleus remains unclear, these results clearly indicate that this atypical nuclear localization of CD133 in a minor subpopulation of cancer cells is a common phenomenon in RMS cell lines.

• MeSH
• antigen AC133 MeSH
• buněčné jádro metabolismus   MeSH
• CD antigeny imunologie   metabolismus   MeSH
• fluorescenční protilátková technika nepřímá MeSH
• glykoproteiny imunologie   metabolismus   MeSH
• lidé MeSH
• monoklonální protilátky imunologie   MeSH
• nádorové biomarkery metabolismus   MeSH
• nádorové buněčné linie MeSH
• peptidy imunologie   metabolismus   MeSH
• rhabdomyosarkom metabolismus   MeSH
• transmisní elektronová mikroskopie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antigen AC133 MeSH
• CD antigeny MeSH
• glykoproteiny MeSH
• monoklonální protilátky MeSH
• nádorové biomarkery MeSH
• peptidy MeSH
• PROM1 protein, human MeSH Prohlížeč
• Prom1 protein, mouse MeSH Prohlížeč